Gilead Sciences Inc [GILD]
$65.04 2.17 (3.23%)
Market Cap 85.46 Billion
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.
EPS 1.55 P/E Ratio 55.20
Previous Earnings Thu, May 2, 2019
Latest Earnings Tue, Jul 30, 2019 (In 9 days)
Yield 3.51% / $2.28
Ex-Date Thu, Dec 13, 2018 (220 days ago)
Pay Date Fri, Dec 28, 2018
|Symbol||Price||Day %||YTD %|
This list of trending stocks may change throughout the trading day.